A Pilot Study of RAI plus Durvalumab Immunotherapy in Patients with Recurrent or Metastatic Thyroid Cancer

Full Title

Radioiodine (RAI) in Combination with Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers


Radioactive iodine (RAI) is a standard treatment for some patients with thyroid cancer. In this study, researchers are assessing the safety and preliminary effectiveness of adding the immunotherapy drug durvalumab to Thyrogen-stimulated RAI in patients with recurrent or metastatic thyroid cancer.

Durvalumab is an immunotherapy drug which blocks PD-L1, a protein cancer cells use to evade detection by the immune system, thereby enabling the immune system to find and kill cancer cells. It is used to treat bladder cancer; its use in this study is investigational. It is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have recurrent or metastatic thyroid cancer.
  • At least 6 months must pass since the completion of any prior RAI therapy and 4 weeks since other cancer treatments and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Alan Ho at 646-888-4235.